[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftT5P2fiYBh7SqfizsOHHvG1iwrjBwHTDnEiKHXo_5PI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Coordinación de Investigación en Salud, Mexico",[4],97,false,12,14,31507,2,65,[14,17,20,22,24,27,29,31],{"name":15,"count":16},"Obesity",7,{"name":18,"count":19},"Hypertension",4,{"name":21,"count":19},"Type 2 Diabetes",{"name":23,"count":19},"Covid19",{"name":25,"count":26},"Obesity, Childhood",3,{"name":28,"count":26},"Insulin Resistance",{"name":30,"count":26},"Inflammation",{"name":32,"count":26},"Liver Cirrhosis",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07248761","Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial","2026-06-30","Intravascular Hydrocortisone (stress dosage): 1 mg\u002Fk\u002Fdose each 8 hours for 5 days",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04031508","Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH","2026-11","lipid injectable emulsion with Fish oil",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,87,111,139,157,185,203,228,255,273,301,319,345,363,390,408,426,453,471,524,562,598,622,645,671,698,716,740,766,790,808,832,855,881,922,953,971,989,1007,1025,1043,1068,1086],{"intervention":38,"totalTrials":53,"cells":54},1,{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":62,"PHASE4":64,"NA":85},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[],{"trials":63,"activeCount":57},[],{"trials":65,"activeCount":53,"soonestReadout":37},[66],{"nctId":35,"briefTitle":36,"status":67,"phases":68,"primaryCompletion":37,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":84},"ACTIVE_NOT_RECRUITING",[49],"2026-07-30","2025-02-01",76,[73,74,75,76,77,78,79,80,81,82,83],"Shock","Preterm Birth Complication","Preterm Intraventricular Hemorrhage","Asphyxia Perinatal","Distress Respiratory Syndrome","Hyperglycaemia (Non Diabetic)","Neonatal Sepsis, Early-Onset","Neonatal Sepsis, Late-Onset","NEC - Necrotizing Enterocolitis","Patent Ductus Arteriosus in Preterm Infants","Intestinal Perforation",[38],{"trials":86,"activeCount":57},[],{"intervention":43,"totalTrials":53,"cells":88},{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":105,"PHASE4":107,"NA":109},{"trials":90,"activeCount":57},[],{"trials":92,"activeCount":57},[],{"trials":94,"activeCount":53,"soonestReadout":42},[95],{"nctId":40,"briefTitle":41,"status":96,"phases":97,"primaryCompletion":42,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":104},"ENROLLING_BY_INVITATION",[47],"2026-12","2019-08-12",40,[102,103],"Pulmonary Hypertension of Newborn","Diaphragm Defect",[43],{"trials":106,"activeCount":57},[],{"trials":108,"activeCount":57},[],{"trials":110,"activeCount":57},[],{"intervention":112,"totalTrials":53,"cells":113},"Pentoxifylline",{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":137},{"trials":115,"activeCount":57},[],{"trials":117,"activeCount":57},[],{"trials":119,"activeCount":57},[],{"trials":121,"activeCount":57},[],{"trials":123,"activeCount":57},[124],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},"NCT01269827","Pentoxifylline and Systemic Inflammation in Hemodialysis Patients","COMPLETED",[49],"2008-05","2006-01",36,[30,133,134],"End-stage Renal Disease","Hemodialysis",[112,136],"starch",{"trials":138,"activeCount":57},[],{"intervention":136,"totalTrials":53,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":155},{"trials":142,"activeCount":57},[],{"trials":144,"activeCount":57},[],{"trials":146,"activeCount":57},[],{"trials":148,"activeCount":57},[],{"trials":150,"activeCount":57},[151],{"nctId":125,"briefTitle":126,"status":127,"phases":152,"primaryCompletion":129,"completion":129,"start":130,"enrollment":131,"conditions":153,"interventions":154},[49],[30,133,134],[112,136],{"trials":156,"activeCount":57},[],{"intervention":158,"totalTrials":53,"cells":159},"Mitomycin C",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":183},{"trials":161,"activeCount":57},[],{"trials":163,"activeCount":57},[],{"trials":165,"activeCount":57},[],{"trials":167,"activeCount":57},[],{"trials":169,"activeCount":57},[170],{"nctId":171,"briefTitle":172,"status":127,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":181},"NCT02199327","Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia",[49],"2016-12-16","2017-07","2014-05",18,[179,180],"Conjunctival Intraepithelial Neoplasia","Corneal Intraepithelial Neoplasia",[158,182],"Interferon Alfa-2b",{"trials":184,"activeCount":57},[],{"intervention":182,"totalTrials":53,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":201},{"trials":188,"activeCount":57},[],{"trials":190,"activeCount":57},[],{"trials":192,"activeCount":57},[],{"trials":194,"activeCount":57},[],{"trials":196,"activeCount":57},[197],{"nctId":171,"briefTitle":172,"status":127,"phases":198,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":199,"interventions":200},[49],[179,180],[158,182],{"trials":202,"activeCount":57},[],{"intervention":204,"totalTrials":53,"cells":205},"bupivacaine",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":226},{"trials":207,"activeCount":57},[],{"trials":209,"activeCount":57},[],{"trials":211,"activeCount":57},[],{"trials":213,"activeCount":57},[],{"trials":215,"activeCount":57},[216],{"nctId":217,"briefTitle":218,"status":127,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT02244086","Analgesic Efficacy of Two Concentrations of Bupivacaine in Women in Labor",[49],"2013-10","2013-06",114,[224],"Obstetric Pain",[204],{"trials":227,"activeCount":57},[],{"intervention":229,"totalTrials":53,"cells":230},"Basiliximab",{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":253},{"trials":232,"activeCount":57},[],{"trials":234,"activeCount":57},[],{"trials":236,"activeCount":57},[],{"trials":238,"activeCount":57},[],{"trials":240,"activeCount":57},[241],{"nctId":242,"briefTitle":243,"status":127,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":251},"NCT03006419","Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients",[49],"2019-07-30","2016-12-01",100,[249,250],"Kidney Transplant Rejection","Kidney Transplant; Complications",[229,252],"Thymoglobulin",{"trials":254,"activeCount":57},[],{"intervention":252,"totalTrials":53,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":271},{"trials":258,"activeCount":57},[],{"trials":260,"activeCount":57},[],{"trials":262,"activeCount":57},[],{"trials":264,"activeCount":57},[],{"trials":266,"activeCount":57},[267],{"nctId":242,"briefTitle":243,"status":127,"phases":268,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":269,"interventions":270},[49],[249,250],[229,252],{"trials":272,"activeCount":57},[],{"intervention":274,"totalTrials":53,"cells":275},"0.9% Sodium Chloride",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":299},{"trials":277,"activeCount":57},[],{"trials":279,"activeCount":57},[],{"trials":281,"activeCount":57},[],{"trials":283,"activeCount":57},[],{"trials":285,"activeCount":57},[286],{"nctId":287,"briefTitle":288,"status":127,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":297},"NCT02233985","Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants",[49],"2017-02","2017-03","2013-08",64,[295,296],"Bronchiolitis","Wheezing",[274,298],"3% Sodium Chloride",{"trials":300,"activeCount":57},[],{"intervention":298,"totalTrials":53,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":317},{"trials":304,"activeCount":57},[],{"trials":306,"activeCount":57},[],{"trials":308,"activeCount":57},[],{"trials":310,"activeCount":57},[],{"trials":312,"activeCount":57},[313],{"nctId":287,"briefTitle":288,"status":127,"phases":314,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":315,"interventions":316},[49],[295,296],[274,298],{"trials":318,"activeCount":57},[],{"intervention":320,"totalTrials":53,"cells":321},"Sequential therapy",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":343},{"trials":323,"activeCount":57},[],{"trials":325,"activeCount":57},[],{"trials":327,"activeCount":57},[],{"trials":329,"activeCount":57},[],{"trials":331,"activeCount":57},[332],{"nctId":333,"briefTitle":334,"status":127,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":341},"NCT02395458","Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens",[49],"2015-02","2013-03",142,[340],"Helicobacter Infections",[320,342],"Triple therapy",{"trials":344,"activeCount":57},[],{"intervention":342,"totalTrials":53,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":361},{"trials":348,"activeCount":57},[],{"trials":350,"activeCount":57},[],{"trials":352,"activeCount":57},[],{"trials":354,"activeCount":57},[],{"trials":356,"activeCount":57},[357],{"nctId":333,"briefTitle":334,"status":127,"phases":358,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":359,"interventions":360},[49],[340],[320,342],{"trials":362,"activeCount":57},[],{"intervention":364,"totalTrials":53,"cells":365},"captopril plus placebo",{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":388},{"trials":367,"activeCount":57},[],{"trials":369,"activeCount":57},[],{"trials":371,"activeCount":57},[],{"trials":373,"activeCount":57},[],{"trials":375,"activeCount":57},[376],{"nctId":377,"briefTitle":378,"status":127,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":385},"NCT01271478","Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients",[49],"2010-12","2013-08-31","2009-08",60,[30,133],[364,386,387],"telmisartan plus placebo","Telmisartan plus Captopril",{"trials":389,"activeCount":57},[],{"intervention":386,"totalTrials":53,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":406},{"trials":393,"activeCount":57},[],{"trials":395,"activeCount":57},[],{"trials":397,"activeCount":57},[],{"trials":399,"activeCount":57},[],{"trials":401,"activeCount":57},[402],{"nctId":377,"briefTitle":378,"status":127,"phases":403,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":404,"interventions":405},[49],[30,133],[364,386,387],{"trials":407,"activeCount":57},[],{"intervention":387,"totalTrials":53,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":424},{"trials":411,"activeCount":57},[],{"trials":413,"activeCount":57},[],{"trials":415,"activeCount":57},[],{"trials":417,"activeCount":57},[],{"trials":419,"activeCount":57},[420],{"nctId":377,"briefTitle":378,"status":127,"phases":421,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":422,"interventions":423},[49],[30,133],[364,386,387],{"trials":425,"activeCount":57},[],{"intervention":427,"totalTrials":53,"cells":428},"Saccharomyces Boulardii Oral",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":437,"NA":451},{"trials":430,"activeCount":57},[],{"trials":432,"activeCount":57},[],{"trials":434,"activeCount":57},[],{"trials":436,"activeCount":57},[],{"trials":438,"activeCount":57},[439],{"nctId":440,"briefTitle":441,"status":127,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":449},"NCT03692299","Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis",[49],"2019-07-26","2015-06",39,[447,448],"Systemic Sclerosis","Small Intestinal Bacterial Overgrowth",[427,450],"Metronidazole",{"trials":452,"activeCount":57},[],{"intervention":450,"totalTrials":53,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":469},{"trials":456,"activeCount":57},[],{"trials":458,"activeCount":57},[],{"trials":460,"activeCount":57},[],{"trials":462,"activeCount":57},[],{"trials":464,"activeCount":57},[465],{"nctId":440,"briefTitle":441,"status":127,"phases":466,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":467,"interventions":468},[49],[447,448],[427,450],{"trials":470,"activeCount":57},[],{"intervention":472,"totalTrials":26,"cells":473},"Triticum Aestivum",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":520,"NA":522},{"trials":475,"activeCount":57},[],{"trials":477,"activeCount":57},[],{"trials":479,"activeCount":57},[],{"trials":481,"activeCount":57},[482,496,509],{"nctId":483,"briefTitle":484,"status":485,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":495},"NCT06496100","Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity","UNKNOWN",[48],"2024-11-27","2024-12-24","2024-01-03",38,[15,492,493,494],"Leptin Deficiency","Ghrelin","Adiponectin",[472],{"nctId":497,"briefTitle":498,"status":127,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":506},"NCT06950138","Efficacy of Triticum Aestivum Over Vascular Function in Mexican Obese Patients",[48],"2025-01-05","2025-02-05","2023-01-03",20,[15,505],"Vascular Risk",[507,508],"Triticum aestivum","calcined magnesia",{"nctId":510,"briefTitle":511,"status":485,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":131,"conditions":516,"interventions":519},"NCT06501248","Effect of Triticum Aestivum vs Placebo on Metabolic Profile Components and Insulin Sensitivity in Patients With Obesity",[48],"2024-08-30","2024-12-10","2022-07-14",[15,517,518],"Drug Effect","Insulin Sensitivity",[472],{"trials":521,"activeCount":57},[],{"trials":523,"activeCount":57},[],{"intervention":525,"totalTrials":11,"cells":526},"4-aminopyridine",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":543,"PHASE4":558,"NA":560},{"trials":528,"activeCount":57},[],{"trials":530,"activeCount":57},[],{"trials":532,"activeCount":57},[533],{"nctId":534,"briefTitle":535,"status":127,"phases":536,"primaryCompletion":537,"completion":290,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT02280096","Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis",[47],"2016-02","2014-10",24,[541],"Multiple Sclerosis",[525],{"trials":544,"activeCount":57},[545],{"nctId":546,"briefTitle":547,"status":485,"phases":548,"primaryCompletion":549,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":556},"NCT03899584","High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.",[48],"2022-12","2023-12","2019-07-17",150,[554,555],"Spinal Cord Injuries","Chronic",[557],"4-Aminopyridine",{"trials":559,"activeCount":57},[],{"trials":561,"activeCount":57},[],{"intervention":563,"totalTrials":11,"cells":564},"Cholecalciferol",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":594,"NA":596},{"trials":566,"activeCount":57},[],{"trials":568,"activeCount":57},[],{"trials":570,"activeCount":57},[],{"trials":572,"activeCount":57},[573,585],{"nctId":574,"briefTitle":575,"status":127,"phases":576,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":584},"NCT04502667","Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19",[48],"2021-03-31","2021-09-15","2020-07-15",45,[23,582,583],"Vitamin D","Children, Only",[563],{"nctId":586,"briefTitle":587,"status":127,"phases":588,"primaryCompletion":589,"completion":590,"start":579,"enrollment":591,"conditions":592,"interventions":593},"NCT04535791","Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers",[48],"2020-12-30","2021-07-15",321,[23,582],[563],{"trials":595,"activeCount":57},[],{"trials":597,"activeCount":57},[],{"intervention":599,"totalTrials":53,"cells":600},"Hydroxychloroquine with Azithromycin",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":618,"NA":620},{"trials":602,"activeCount":57},[],{"trials":604,"activeCount":57},[],{"trials":606,"activeCount":57},[],{"trials":608,"activeCount":57},[609],{"nctId":610,"briefTitle":611,"status":485,"phases":612,"primaryCompletion":613,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":617},"NCT04964583","Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19",[47,48],"2021-08","2021-01-20",105,[23],[599],{"trials":619,"activeCount":57},[],{"trials":621,"activeCount":57},[],{"intervention":623,"totalTrials":53,"cells":624},"Pantoprazole",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":641,"NA":643},{"trials":626,"activeCount":57},[],{"trials":628,"activeCount":57},[],{"trials":630,"activeCount":57},[],{"trials":632,"activeCount":57},[633],{"nctId":634,"briefTitle":635,"status":127,"phases":636,"primaryCompletion":337,"completion":637,"start":638,"enrollment":9,"conditions":639,"interventions":640},"NCT01541735","Pantoprazole on Insulin Secretion in Diabetes",[47,48],"2013-05","2012-01",[21],[623],{"trials":642,"activeCount":57},[],{"trials":644,"activeCount":57},[],{"intervention":646,"totalTrials":53,"cells":647},"Melatonin 10 MG",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":654,"PHASE4":667,"NA":669},{"trials":649,"activeCount":57},[],{"trials":651,"activeCount":57},[],{"trials":653,"activeCount":57},[],{"trials":655,"activeCount":57},[656],{"nctId":657,"briefTitle":658,"status":485,"phases":659,"primaryCompletion":660,"completion":661,"start":662,"enrollment":247,"conditions":663,"interventions":666},"NCT05857046","Cerebroprotective Effect of Melatonin in Stroke",[48],"2025-03-15","2025-07-14","2024-03-01",[664,665],"Stroke, Acute Ischemic","Strokes Thrombotic",[646],{"trials":668,"activeCount":57},[],{"trials":670,"activeCount":57},[],{"intervention":672,"totalTrials":53,"cells":673},"Collagen-PVP",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":694,"NA":696},{"trials":675,"activeCount":57},[],{"trials":677,"activeCount":57},[],{"trials":679,"activeCount":57},[],{"trials":681,"activeCount":57},[682],{"nctId":683,"briefTitle":684,"status":485,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":693},"NCT04019782","Collagen-PVP vs Hylan G-F 20 in the Treatment of Knee Osteoarthritis",[48],"2021-02-28","2021-08-31","2019-08-01",120,[691,692],"Knee Osteoarthritis","Gonarthrosis",[672],{"trials":695,"activeCount":57},[],{"trials":697,"activeCount":57},[],{"intervention":508,"totalTrials":53,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":712,"NA":714},{"trials":701,"activeCount":57},[],{"trials":703,"activeCount":57},[],{"trials":705,"activeCount":57},[],{"trials":707,"activeCount":57},[708],{"nctId":497,"briefTitle":498,"status":127,"phases":709,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":710,"interventions":711},[48],[15,505],[507,508],{"trials":713,"activeCount":57},[],{"trials":715,"activeCount":57},[],{"intervention":717,"totalTrials":53,"cells":718},"omega 3 fatty acids",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":736,"NA":738},{"trials":720,"activeCount":57},[],{"trials":722,"activeCount":57},[],{"trials":724,"activeCount":57},[],{"trials":726,"activeCount":57},[727],{"nctId":728,"briefTitle":729,"status":127,"phases":730,"primaryCompletion":176,"completion":444,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT02041520","Effect of Omega 3 Fatty Acids on Oxidative Stress in HIV Seropositive Patients",[48],"2013-01",70,[734],"HIV\u002FAIDS",[717],{"trials":737,"activeCount":57},[],{"trials":739,"activeCount":57},[],{"intervention":741,"totalTrials":53,"cells":742},"alprazolam 1mg",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":744,"activeCount":57},[],{"trials":746,"activeCount":57},[],{"trials":748,"activeCount":57},[749],{"nctId":750,"briefTitle":751,"status":485,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT03702803","Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety.",[47],"2020-09-19","2020-10-19","2016-03-16",122,[758],"Generalized Anxiety Disorder",[741],{"trials":761,"activeCount":57},[],{"trials":763,"activeCount":57},[],{"trials":765,"activeCount":57},[],{"intervention":767,"totalTrials":53,"cells":768},"Favipiravir",{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":770,"activeCount":57},[],{"trials":772,"activeCount":57},[],{"trials":774,"activeCount":57},[775],{"nctId":776,"briefTitle":777,"status":127,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":689,"conditions":781,"interventions":782},"NCT04918927","Favipiravir +\u002F- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19",[47],"2023-03-21","2021-10-12",[23],[767,783],"Nitazoxanide",{"trials":785,"activeCount":57},[],{"trials":787,"activeCount":57},[],{"trials":789,"activeCount":57},[],{"intervention":783,"totalTrials":53,"cells":791},{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":793,"activeCount":57},[],{"trials":795,"activeCount":57},[],{"trials":797,"activeCount":57},[798],{"nctId":776,"briefTitle":777,"status":127,"phases":799,"primaryCompletion":779,"completion":779,"start":780,"enrollment":689,"conditions":800,"interventions":801},[47],[23],[767,783],{"trials":803,"activeCount":57},[],{"trials":805,"activeCount":57},[],{"trials":807,"activeCount":57},[],{"intervention":809,"totalTrials":53,"cells":810},"Diclofenac Sodium Gel",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":812,"activeCount":57},[],{"trials":814,"activeCount":57},[],{"trials":816,"activeCount":57},[817],{"nctId":818,"briefTitle":819,"status":485,"phases":820,"primaryCompletion":821,"completion":822,"start":823,"enrollment":247,"conditions":824,"interventions":825},"NCT04511195","Effectiveness and Safety of Sphaeralcea Angustifolia Standardized Extract as a Topical Treatment of Knee Osteoarthritis",[47],"2021-01-16","2021-06-16","2020-07-10",[691],[809],{"trials":827,"activeCount":57},[],{"trials":829,"activeCount":57},[],{"trials":831,"activeCount":57},[],{"intervention":833,"totalTrials":53,"cells":834},"Diacerein",{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":836,"activeCount":57},[],{"trials":838,"activeCount":57},[],{"trials":840,"activeCount":57},[841],{"nctId":842,"briefTitle":843,"status":127,"phases":844,"conditions":845,"interventions":848},"NCT01298882","Diacerein on Insulin Secretion in Diabetes",[47],[846,847,15],"Type 2 Diabetes Mellitus","Overweight",[833],{"trials":850,"activeCount":57},[],{"trials":852,"activeCount":57},[],{"trials":854,"activeCount":57},[],{"intervention":856,"totalTrials":53,"cells":857},"Pioglitazone",{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":859,"activeCount":57},[],{"trials":861,"activeCount":57},[],{"trials":863,"activeCount":57},[864],{"nctId":865,"briefTitle":866,"status":127,"phases":867,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":873},"NCT01396564","Pioglitazone and Metformin in Diabetic Children",[46,47],"2006-10","2011-07","2005-10",56,[21],[874,856],"Metformin",{"trials":876,"activeCount":57},[],{"trials":878,"activeCount":57},[],{"trials":880,"activeCount":57},[],{"intervention":874,"totalTrials":26,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":893,"PHASE4":906,"NA":908},{"trials":884,"activeCount":57},[],{"trials":886,"activeCount":57},[],{"trials":888,"activeCount":57},[889],{"nctId":865,"briefTitle":866,"status":127,"phases":890,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":891,"interventions":892},[46,47],[21],[874,856],{"trials":894,"activeCount":57},[895],{"nctId":896,"briefTitle":897,"status":127,"phases":898,"primaryCompletion":899,"completion":869,"start":900,"enrollment":901,"conditions":902,"interventions":905},"NCT01394887","Metformin & Inflammation in Pre-diabetic Children",[47,48],"2003-07","2002-07",52,[903,30,904],"Glucose Intolerance","Diabetes",[874],{"trials":907,"activeCount":57},[],{"trials":909,"activeCount":57},[910],{"nctId":911,"briefTitle":912,"status":913,"phases":914,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":921},"NCT02521753","Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients","TERMINATED",[50],"2020-08","2025-03","2015-08",123,[920,15],"Polycystic Ovary Syndrome",[874],{"intervention":923,"totalTrials":53,"cells":924},"Intermittent Piperacillin\u002Ftazobactam",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":926,"activeCount":57},[],{"trials":928,"activeCount":57},[],{"trials":930,"activeCount":57},[],{"trials":932,"activeCount":57},[],{"trials":934,"activeCount":57},[],{"trials":936,"activeCount":57},[937],{"nctId":938,"briefTitle":939,"status":127,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":947},"NCT03019965","Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis",[50],"2019-12-30","2020-01-30","2017-02-01",426,[946],"Sepsis",[923,948,949,950,951,952],"Continuous Piperacillin\u002Ftazobactam","Intermittent Imipenem","Extended Imipenem","Intermittent Meropenem","Extended Meropenem",{"intervention":948,"totalTrials":53,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":956,"activeCount":57},[],{"trials":958,"activeCount":57},[],{"trials":960,"activeCount":57},[],{"trials":962,"activeCount":57},[],{"trials":964,"activeCount":57},[],{"trials":966,"activeCount":57},[967],{"nctId":938,"briefTitle":939,"status":127,"phases":968,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":969,"interventions":970},[50],[946],[923,948,949,950,951,952],{"intervention":949,"totalTrials":53,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":974,"activeCount":57},[],{"trials":976,"activeCount":57},[],{"trials":978,"activeCount":57},[],{"trials":980,"activeCount":57},[],{"trials":982,"activeCount":57},[],{"trials":984,"activeCount":57},[985],{"nctId":938,"briefTitle":939,"status":127,"phases":986,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":987,"interventions":988},[50],[946],[923,948,949,950,951,952],{"intervention":950,"totalTrials":53,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":997,"PHASE4":999,"NA":1001},{"trials":992,"activeCount":57},[],{"trials":994,"activeCount":57},[],{"trials":996,"activeCount":57},[],{"trials":998,"activeCount":57},[],{"trials":1000,"activeCount":57},[],{"trials":1002,"activeCount":57},[1003],{"nctId":938,"briefTitle":939,"status":127,"phases":1004,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":1005,"interventions":1006},[50],[946],[923,948,949,950,951,952],{"intervention":951,"totalTrials":53,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1010,"activeCount":57},[],{"trials":1012,"activeCount":57},[],{"trials":1014,"activeCount":57},[],{"trials":1016,"activeCount":57},[],{"trials":1018,"activeCount":57},[],{"trials":1020,"activeCount":57},[1021],{"nctId":938,"briefTitle":939,"status":127,"phases":1022,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":1023,"interventions":1024},[50],[946],[923,948,949,950,951,952],{"intervention":952,"totalTrials":53,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1028,"activeCount":57},[],{"trials":1030,"activeCount":57},[],{"trials":1032,"activeCount":57},[],{"trials":1034,"activeCount":57},[],{"trials":1036,"activeCount":57},[],{"trials":1038,"activeCount":57},[1039],{"nctId":938,"briefTitle":939,"status":127,"phases":1040,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":1041,"interventions":1042},[50],[946],[923,948,949,950,951,952],{"intervention":1044,"totalTrials":53,"cells":1045},"Propofol",{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1052,"PHASE4":1054,"NA":1056},{"trials":1047,"activeCount":57},[],{"trials":1049,"activeCount":57},[],{"trials":1051,"activeCount":57},[],{"trials":1053,"activeCount":57},[],{"trials":1055,"activeCount":57},[],{"trials":1057,"activeCount":57},[1058],{"nctId":1059,"briefTitle":1060,"status":485,"phases":1061,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":100,"conditions":1064,"interventions":1066},"NCT03233815","Benefits of Total Intravenous Anesthesia Compared With Inhaled Anesthesia in Cardiovascular Surgery",[],"2021-12","2017-11-13",[1065],"Cardiovascular Surgical Procedure",[1044,1067],"Sevoflurane",{"intervention":1067,"totalTrials":53,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1071,"activeCount":57},[],{"trials":1073,"activeCount":57},[],{"trials":1075,"activeCount":57},[],{"trials":1077,"activeCount":57},[],{"trials":1079,"activeCount":57},[],{"trials":1081,"activeCount":57},[1082],{"nctId":1059,"briefTitle":1060,"status":485,"phases":1083,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":100,"conditions":1084,"interventions":1085},[],[1065],[1044,1067],{"intervention":1087,"totalTrials":53,"cells":1088},"Rifaximin",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1090,"activeCount":57},[],{"trials":1092,"activeCount":57},[],{"trials":1094,"activeCount":57},[],{"trials":1096,"activeCount":57},[],{"trials":1098,"activeCount":57},[],{"trials":1100,"activeCount":57},[1101],{"nctId":1102,"briefTitle":1103,"status":913,"phases":1104,"primaryCompletion":1105,"completion":1105,"start":1106,"enrollment":1107,"conditions":1108,"interventions":1109},"NCT02439307","Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial",[50],"2021-07-26","2017-02-28",11,[448,32],[1087]]